Program
Anti-PRL-3 Monoclonal Antibody PRL3-zumab
Also written as “PRL3-ZUMAB” and “PRL3-zumab”.
Its studies are mostly in Macular Degeneration · Neoplasms, led by Intra-IMMUSG Pte.
Drug pageAnti-PRL-3 Monoclonal Antibody PRL3-zumab: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Intra-IMMUSG Pte | 44 open or running | phase 3since Nov 24, 2025 | Jun 22, 2020 | Dec 2026phase 3 · NCT07290088 |
Also a collaborator on its studies: Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2020First study: phase 2 study in NeoplasmsFirst studyNCT04452955 · 51 enrolled · United States
- Nov 24, 2025Phase 3 study in Advanced Solid CancersPhase 3 reachedNCT07290088 · 52 planned · Malaysia
- Apr 15, 20262 phase 2 studiesNCT07541001, NCT07547228
Ahead
- Dec 2026Primary completion: phase 3 study in Advanced Solid CancersNCT07290088
- Dec 1, 2026Primary completion: phase 2 study in NeoplasmsNCT04452955
- Feb 7, 2027Primary completion: phase 2 study in Neovascular Age Related Macular DegenerationNCT07547228
TargetBeta
“A humanized monoclonal antibody against phosphatase of regenerating liver 3 (PRL-3; PTP4A3), ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07547228Neovascular Age Related Macular Degeneration · Singapore | 2 | Recruiting | Feb 7, 2027 | 15 |
| NCT07541001Advanced Malignant Solid Tumor · China | 2 | Active, not recruiting | Jun 1, 2026 | 60 |
| NCT07290088Advanced Solid Cancers · Malaysia | 3 | Recruiting | Dec 2026 | 52 |
| NCT04452955Neoplasms · United States | 2 | Active, not recruiting | Dec 1, 2026 | 51 |
How it is read
Names in the registry
- “PRL3-ZUMAB”, 3 entries
- “PRL3-zumab”, 1 entry
Conditions, from the studies’ own filings
- Macular Degeneration, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.